Sign Up to like & get
recommendations!
0
Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.8_suppl.141
Abstract: 141 Background: Dabrafenib plus trametinib (D+T), ipilimumab plus nivolumab (I+N), and both nivolumab and pembrolizumab (“PD-1 mono”) are approved for the 1L treatment of MM. This study reports real world 1L TTNT for patients receiving…
read more here.
Keywords:
initiation;
treatment;
ipi nivo;
ttnt ... See more keywords